US EditionPublished • loading... • Updated
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Lynx1, holding 16.3% of shares, urges shareholder vote for two independent directors to counter dilution and mismanagement with a $4.75 per share cash offer.
- On December 2, 2025, Lynx1 Master Fund LP resubmitted an all-cash proposal to acquire all outstanding shares of Neuphoria for $4.75 per share, sending an open letter from Dorado, Puerto Rico with a 16% premium.
- Rapidly, the Company issued more than 3 million shares, representing a 128% increase in shares outstanding, and on November 14, 2025 disclosed intent to raise $20 million via its ATM, forcing Lynx1 to withdraw its initial offer on November 18, 2025.
- Lynx1 nominated Dr. Stephen Doberstein, Ph.D. and Kimberly Smith as independent nominees on November 24, 2025, highlighting their biotech and capital-markets expertise and potential to hold two of five Board seats.
- Lynx1 urged shareholders to vote FOR both Independent Nominees on the BLUE universal proxy card and to WITHHOLD on the Company's nominees, saying the nominees would oversee a disciplined, transparent strategic review.
- The Board adopted entrenchment measures that Lynx1 says disenfranchised over 55% of shareholders, including a poison pill and a 128% increase in shares outstanding, while H.C. Wainwright earns a 3% commission.
Insights by Ground AI
38 Articles
38 Articles
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Submits Recalculated Initial Offer of $4.75 Based on Board's Value Destructive ActionsNominated Two Independent Candidates to Restore Oversight and Protect ShareholdersUrges Shareholders to Vote FOR Lynx1's
·New York, United States
Read Full ArticleCoverage Details
Total News Sources38
Leaning Left4Leaning Right4Center16Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
